Biohaven (NYSE:BHVN) Stock Crosses Below Fifty Day Moving Average - What's Next?

Biohaven logo with Healthcare background
Image from MarketBeat Media, LLC.

Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $13.45 and traded as low as $13.18. Biohaven shares last traded at $13.2470, with a volume of 1,567,879 shares trading hands.

Analyst Upgrades and Downgrades

BHVN has been the topic of several analyst reports. HC Wainwright reaffirmed a "neutral" rating and set a $10.00 target price on shares of Biohaven in a report on Thursday, September 10th. Robert W. Baird set a $48.00 price target on Biohaven in a research report on Thursday, October 22nd. Raymond James Financial reissued a "strong-buy" rating on shares of Biohaven in a report on Thursday, October 8th. Morgan Stanley upped their price objective on Biohaven from $19.00 to $21.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 3rd. Finally, Royal Bank Of Canada upped their price objective on Biohaven from $19.00 to $22.00 and gave the stock a "sector perform" rating in a research report on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Biohaven currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.14.

Check Out Our Latest Analysis on Biohaven

Biohaven Price Performance

The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 21.23. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -3.43 and a beta of 1.36. The stock's 50-day simple moving average is $13.45 and its two-hundred day simple moving average is $12.36.

Hedge Funds Weigh In On Biohaven

Several hedge funds and other institutional investors have recently made changes to their positions in BHVN. Janus Henderson Group PLC boosted its stake in shares of Biohaven by 1,145.9% in the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock valued at $148,214,000 after purchasing an additional 16,127,247 shares during the period. BlackRock Inc. acquired a new position in shares of Biohaven in the 2nd quarter valued at $196,574,000. Jupiter Topco LLC acquired a new stake in shares of Biohaven in the 2nd quarter valued at about $127,852,000. Goldman Sachs Group Inc. grew its position in shares of Biohaven by 44.3% during the third quarter. Goldman Sachs Group Inc. now owns 3,728,221 shares of the company's stock worth $49,772,000 after acquiring an additional 1,145,175 shares during the last quarter. Finally, Stempoint Capital LP purchased a new position in Biohaven during the 1st quarter worth $13,489,000. Hedge funds and other institutional investors own 88.78% of the company's stock.

About Biohaven

(Get Free Report)

Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies. The company's pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biohaven Right Now?

Before you consider Biohaven, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.

While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines